Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Series B brings in $43mm for CNS start-up NeuroTherapeutics

21 May 2010

Executive Summary

First-time investors MPM Capital and SR One have co-led the $43mm Series B financing for NeuroTherapeutics Pharma Inc. (diseases caused by a hyperexcitable central nervous system). Fidelity Biosciences and Pfizer Venture Investments, other new backers, also participated along with returning shareholders Novo Ventures and Thomas McNerney & Partners. All of the new investors have contributed board members to the company.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By